Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors - Concepedia

Concepedia

Publication | Open Access

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

DOI Full Paper Access

870

Citations

13

References

2004

Year

Dirk Strumberg, Heike Richly, Ralf A. Hilger, N. Schleucher, Sönke Korfee, Mitra Tewes, Markus Faghih, E. Brendel, D. Voliotis, Claus G. Haase,

Journal of Clinical Oncology

Abstract

Oral BAY 43-9006 was well tolerated and appeared to provide some clinical benefits. Based on the results of this study, BAY 43-9006 at 400 mg bid continuous is recommended for ongoing and future studies.

References

	Year	Citations

Page 1